SV2013004496A - Inhibidor dual de cinasa pi3/mtor - Google Patents

Inhibidor dual de cinasa pi3/mtor

Info

Publication number
SV2013004496A
SV2013004496A SV2013004496A SV2013004496A SV2013004496A SV 2013004496 A SV2013004496 A SV 2013004496A SV 2013004496 A SV2013004496 A SV 2013004496A SV 2013004496 A SV2013004496 A SV 2013004496A SV 2013004496 A SV2013004496 A SV 2013004496A
Authority
SV
El Salvador
Prior art keywords
mtor
kinase
dual inhibitor
ona
pi3k
Prior art date
Application number
SV2013004496A
Other languages
English (en)
Inventor
David Anthony Barda
Mary Margaret Mader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2013004496A publication Critical patent/SV2013004496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA, O UNA SAL DEL MISMO FARMACÉUTICAMENTE ACEPTABLE, QUE INHIBE TANTO PI3K COMO MTOR Y, POR LO TANTO, ES ÚTIL EN EL TRATAMIENTO DE CÁNCER
SV2013004496A 2011-01-14 2013-07-12 Inhibidor dual de cinasa pi3/mtor SV2013004496A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
SV2013004496A true SV2013004496A (es) 2017-11-07

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2013004496A SV2013004496A (es) 2011-01-14 2013-07-12 Inhibidor dual de cinasa pi3/mtor

Country Status (39)

Country Link
US (2) US8440829B2 (es)
EP (1) EP2663564B1 (es)
JP (1) JP5891247B2 (es)
KR (1) KR101561360B1 (es)
CN (1) CN103282364B (es)
AR (1) AR084551A1 (es)
AU (1) AU2012205619B2 (es)
BR (1) BR112013017672A2 (es)
CA (1) CA2824760C (es)
CL (1) CL2013002005A1 (es)
CO (1) CO6731133A2 (es)
CR (1) CR20130289A (es)
CY (1) CY1116007T1 (es)
DK (1) DK2663564T3 (es)
DO (1) DOP2013000158A (es)
EA (1) EA022163B1 (es)
EC (1) ECSP13012764A (es)
ES (1) ES2531891T3 (es)
GT (1) GT201300180A (es)
HK (1) HK1188454A1 (es)
HR (1) HRP20150135T1 (es)
HU (1) HUE024426T2 (es)
IL (1) IL227165A (es)
JO (1) JO3003B1 (es)
ME (1) ME02019B (es)
MX (1) MX2013008185A (es)
MY (1) MY164705A (es)
PE (1) PE20140864A1 (es)
PL (1) PL2663564T3 (es)
PT (1) PT2663564E (es)
RS (1) RS53828B1 (es)
SG (1) SG191744A1 (es)
SI (1) SI2663564T1 (es)
SV (1) SV2013004496A (es)
TN (1) TN2013000237A1 (es)
TW (1) TWI518086B (es)
UA (1) UA109921C2 (es)
WO (1) WO2012097039A1 (es)
ZA (1) ZA201304757B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
MX2018007225A (es) 2015-12-15 2018-08-01 Lilly Co Eli Terapia combinada para el cancer.
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2017180389A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer
JP6911048B2 (ja) * 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
CN109475629A (zh) 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) * 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
EP4269594A3 (en) 2017-02-17 2023-12-20 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
AU2020468487B2 (en) 2020-09-21 2024-02-29 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo(4,5-c) quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
CA2598656A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US8088790B2 (en) 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
US20100311714A1 (en) 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
BRPI1010621A2 (pt) 2009-06-04 2016-06-21 Novartis Ag derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
AU2009349135A1 (en) * 2009-06-30 2012-02-16 Piramal Enterprises Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
AR084731A1 (es) * 2010-12-06 2013-06-05 Piramal Life Sciences Ltd Derivados de imidazoquinolina sustituidos
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
ME02019B (me) 2015-05-20
PL2663564T3 (pl) 2015-05-29
PE20140864A1 (es) 2014-07-19
CN103282364A (zh) 2013-09-04
NZ611541A (en) 2015-02-27
BR112013017672A2 (pt) 2018-09-18
EP2663564B1 (en) 2014-12-17
CL2013002005A1 (es) 2013-12-27
DOP2013000158A (es) 2013-11-30
CY1116007T1 (el) 2017-01-25
AU2012205619A1 (en) 2013-06-27
JO3003B1 (ar) 2016-09-05
JP5891247B2 (ja) 2016-03-22
US20120184577A1 (en) 2012-07-19
UA109921C2 (uk) 2015-10-26
CN103282364B (zh) 2015-06-17
TWI518086B (zh) 2016-01-21
TN2013000237A1 (en) 2014-11-10
EA022163B1 (ru) 2015-11-30
US20130237562A1 (en) 2013-09-12
EA201390823A1 (ru) 2013-12-30
SG191744A1 (en) 2013-08-30
MX2013008185A (es) 2013-08-21
CA2824760C (en) 2016-03-15
TW201307343A (zh) 2013-02-16
KR20130116302A (ko) 2013-10-23
WO2012097039A1 (en) 2012-07-19
EP2663564A1 (en) 2013-11-20
PT2663564E (pt) 2015-02-24
RS53828B1 (en) 2015-06-30
US8440829B2 (en) 2013-05-14
US8658668B2 (en) 2014-02-25
MY164705A (en) 2018-01-30
CA2824760A1 (en) 2012-07-19
JP2014502638A (ja) 2014-02-03
AR084551A1 (es) 2013-05-22
CR20130289A (es) 2013-10-07
IL227165A (en) 2016-06-30
GT201300180A (es) 2014-04-08
HK1188454A1 (en) 2014-05-02
ECSP13012764A (es) 2013-09-30
HRP20150135T1 (en) 2015-03-13
KR101561360B1 (ko) 2015-10-16
ZA201304757B (en) 2014-12-23
CO6731133A2 (es) 2013-08-15
ES2531891T3 (es) 2015-03-20
SI2663564T1 (sl) 2015-01-30
HUE024426T2 (en) 2016-01-28
AU2012205619B2 (en) 2015-05-21
DK2663564T3 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
SV2013004496A (es) Inhibidor dual de cinasa pi3/mtor
ECSP14017584A (es) Compuestos inhibidores de raf
CR20110339A (es) Compuestos útiles para inhibir chk1
PA8740901A1 (es) Compuestos organicos
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
ES2609857T3 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H-imidazo[4,5-C]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominios
PL2694485T3 (pl) Kombinacja związku inhibitora akt i wemurafenibu do zastosowania w leczeniach terapeutycznych
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
ECSP11011157A (es) Inhibidores de proteína cinasa
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
NI201300038A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
DOP2011000260A (es) Pirimidinas fusionadas
BR112015009649A2 (pt) composto de triazolo
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
ECSP13012994A (es) COMBINACIÓN DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) Y UN INHIBIDOR DE mTOR
BR112017005324A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
TH149217B (th) สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้ง คู่สำหรับ Pl3 คิเนส/MTOR
CU20100148A7 (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis